CRC development is often initiated by acquiring loss-of-function mutations in the APC gene, which is observed in approximately 80% of CRC cases, followed by the accumulation of mutations in major driver genes, such as KRAS (~40%), SMAD4 (~10%), and TP53 (~50%), leading to malignant progression1. The gene discussed is TP53; the disease is colorectal carcinoma.